Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension trial of fesoterodine for treatment of overactive bladder syndrome
2004-000476-13Phase 3Completed
- Sponsor
- Schwarz Pharma
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fesoterodine in overactive bladder (OAB), sponsored by Schwarz Pharma. Primary endpoint: Safety and tolerability (adverse events). Started Jun 2004; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2004-000476-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000476-13.